Childhood Apraxia of Speech Trial
The Murdoch Children’s Research Institute is trialling a new treatment for children with childhood apraxia of speech (CAS). This treatment is the drug methylphenidate (MPH), commonly known as Ritalin. We want to find out whether MPH can help improve the speech and language symptoms of CAS in children aged 6-12 years.
MPH is approved as a treatment for ADHD in children. We want to find out if it is effective for children with CAS.
To be eligible to participate in the trial, children must:
- have a confirmed diagnosis of CAS. If your child does not have a confirmed diagnosis, we will assess their speech
- be aged 6-12 years
- be able to complete spoken tasks
- not have epilepsy, congenital heart disease, severe Tourette Syndrome or severe intellectual disability
- who live within 250 km of Murdoch Children's Research Institute
- who have some inattentive and/or hyperactive symptoms. If you are unsure whether your child has these symptoms, we will measure these.
The trial will last for 2 months. It will involve only one visit to RCH for an initial health and medical screening. It will also involve four Zoom calls with the study team for speech and language assessments.
Register your interest in the trial
If you would like to find out more about the study, please contact the study team: speechtrial@mcri.edu.au
Proudly in partnership with
